Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

UG Healthcare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

UG Healthcare şirketinin toplam hissedar öz sermayesi SGD161.3M ve toplam borcu SGD42.8M olup, bu da borç-öz sermaye oranını 26.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SGD225.3M ve SGD64.1M dir.

Anahtar bilgiler

26.6%

Borç/özkaynak oranı

S$42.83m

Borç

Faiz karşılama oranı	n/a
Nakit	S$28.00m
Eşitlik	S$161.28m
Toplam yükümlülükler	S$64.07m
Toplam varlıklar	S$225.35m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 8K7 'nin kısa vadeli varlıkları ( SGD145.1M ) kısa vadeli yükümlülüklerini ( SGD37.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 8K7 şirketinin kısa vadeli varlıkları ( SGD145.1M ) uzun vadeli yükümlülüklerini ( SGD27.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 8K7 'nin net borç/öz sermaye oranı ( 9.2% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 8K7 'nin borç/öz sermaye oranı son 5 yılda 88.2% seviyesinden 26.6% seviyesine düştü.

Borç Kapsamı: 8K7 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: 8K7 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

UG Healthcare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Full year 2024 earnings released: S$0.01 loss per share (vs S$0.033 loss in FY 2023)

UG Healthcare Corporation Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

UG Healthcare Corporation Limited (Catalist:8K7) completed the acquisition of 50% stake in UG NITREX, S. L. from Afaprot, S. L. and Martínez for €0.5 million.

First half 2024 earnings released: S$0.008 loss per share (vs S$0.008 loss in 1H 2023)

New major risk - Revenue and earnings growth

UG Healthcare Corporation Limited to Report First Half, 2024 Results on Feb 13, 2024

UG Healthcare Corporation Limited Announces Appointment of Ng Lee Eng as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

New minor risk - Share price stability

UG Healthcare Corporation Limited Announces Cessation Vincent Leow as Independent Non-Executive Director Chairman of Nominating Committee Member of Audit Committee Member of Remuneration Committee

Full year 2023 earnings released: S$0.033 loss per share (vs S$0.059 profit in FY 2022)

UG Healthcare Corporation Limited, Annual General Meeting, Oct 30, 2023

Full year 2023 earnings released: S$0.033 loss per share (vs S$0.059 profit in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: S$0.008 loss per share (vs S$0.034 profit in 1H 2022)

UG Healthcare Corporation Limited to Report First Half, 2023 Results on Feb 14, 2023

Less than half of directors are independent

UG Healthcare Corporation Limited Approves Special Cash Dividend for the Financial Year Ended 30 June 2022, Payable on 16 December 2022

UG Healthcare Corporation Limited (Catalist:8K7) entered into a share sale agreement to acquire Indigo Teguh Sdn Bhd from Lee Keck Keong for MYR 100.

Full year 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited, Annual General Meeting, Oct 28, 2022

Consensus revenue estimates fall by 12%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited Recommends Tax Exempt Special Dividend for Fiscal Year 2022

Less than half of directors are independent

Now 20% undervalued after recent price drop

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

UG Healthcare Corporation Limited to Report First Half, 2022 Results on Feb 11, 2022

UG Healthcare Corporation Limited to Report First Half, 2022 Results on Feb 11, 2022

Price target decreased to S$0.44

Full year 2021 earnings released: EPS S$0.19 (vs S$0.023 in FY 2020)

Price target decreased to S$0.55

Less than half of directors are independent

UG Healthcare Corporation Limited Provides Update on Covid-19 Situation in the Group's Manufacturing Division in Malaysia

Company Secretary Kar Yeoh has left the company

Third quarter 2021 earnings released: EPS S$0.056 (vs S$0.011 in 3Q 2020)

Price target decreased to S$0.99

Second quarter 2021 earnings released

UG Healthcare Corporation Limited to Report First Half, 2021 Results on Feb 04, 2021

New 90-day low: S$0.36

New 90-day low: S$0.23

New 90-day low: S$0.60

New 90-day low: S$0.64

First quarter 2021 earnings released: EPS S$0.039

Analysts update estimates

Annual earnings released: Revenue and earnings beat expectations

Full year earnings released - EPS S$0.023

Analysts increase revenue estimates to S$240.3m

UG Healthcare Corporation Limited has completed a Follow-on Equity Offering in the amount of SGD 19.0875 million.

Analysts increase revenue estimates to S$180.9m

Full year earnings released - EPS S$0.068

New 90-day high - S$2.91

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin